Cancer Biology Laboratory, Institute of Life Sciences (Government of India), Nalco Square, Bhubaneswar, Odisha, 751023, India.
National Central University, Chungli, Taiwan.
BMC Cancer. 2017 Dec 15;17(1):858. doi: 10.1186/s12885-017-3863-7.
Well-known anti-malarial drug artemisinin exhibits potent anti-cancerous activities. In-vivo and in-vitro studies showed its anti-tumor and immunomodulatory properties signifying it as a potent drug candidate for study. The studies of mechanisms of cell movement are relevant which can be understood by knowing the involvement of genes in an effect of a drug. Although cytotoxicity and anti-proliferative activity of artemisinin is evident, the genes participating in its anti-migratory and reduced invasive effect are not well studied. The present study reports the alteration in the expression of 84 genes involved in cell motility upon artemisinin treatment in MCF-7 breast cancer cells using pathway focused gene expression PCR array. In addition, the effect of artemisinin on epigenetic modifier HDACs is studied.
We checked the functional stimulus of artemisinin on cell viability, migration, invasion and apoptosis in breast cancerous cell lines. Using qRT-PCR and western blot, we validated the altered expression of relevant genes associated with proliferation, migration, invasion, apoptosis and mammary gland development.
Artemisinin inhibited cell proliferation of estrogen receptor negative breast cancer cells with fewer efficacies in comparison to estrogen receptor positive ones. At the same time, cell viability and proliferation of normal breast epithelial MCF10A cells was un-affected. Artemisinin strongly inhibited cancer cell migration and invasion. Along with orphan nuclear receptors (ERRα, ERRβ and ERRγ), artemisinin altered the ERα/ERβ/PR/Her expression status of MCF-7 cells. The expression of genes involved in the signaling pathways associated with proliferation, migration, invasion and apoptosis was significantly altered which cooperatively resulted into reduced growth promoting activities of breast cancer cells. Interestingly, artemisinin exhibited inhibitory effect on histone deacetylases (HDACs).
Upregulated expression of tumor suppressor genes along with reduced expression of oncogenes significantly associated with growth stimulating signaling pathways in response to artemisinin treatment suggests its efficacy as an effective drug in breast cancer treatment.
众所周知的抗疟药物青蒿素具有很强的抗癌活性。体内和体外研究表明其具有抗肿瘤和免疫调节特性,表明它是一种很有前途的研究候选药物。研究细胞运动的机制是相关的,可以通过了解基因在药物作用中的参与来理解。虽然青蒿素的细胞毒性和抗增殖活性是明显的,但参与其抗迁移和减少侵袭作用的基因尚未得到很好的研究。本研究报告了青蒿素处理 MCF-7 乳腺癌细胞后,参与细胞运动的 84 个基因的表达变化,使用通路聚焦基因表达 PCR 阵列。此外,还研究了青蒿素对表观遗传修饰酶 HDACs 的影响。
我们检查了青蒿素对乳腺癌细胞系活力、迁移、侵袭和凋亡的功能刺激作用。通过 qRT-PCR 和 Western blot,我们验证了与增殖、迁移、侵袭、凋亡和乳腺发育相关的相关基因的表达变化。
青蒿素抑制了雌激素受体阴性乳腺癌细胞的增殖,其效果比雌激素受体阳性细胞差。同时,正常乳腺上皮 MCF10A 细胞的细胞活力和增殖不受影响。青蒿素强烈抑制癌细胞迁移和侵袭。与孤儿核受体(ERRα、ERRβ 和 ERRγ)一起,青蒿素改变了 MCF-7 细胞的 ERα/ERβ/PR/Her 表达状态。与增殖、迁移、侵袭和凋亡相关的信号通路中涉及的基因表达明显改变,共同导致乳腺癌细胞生长促进活性降低。有趣的是,青蒿素对组蛋白去乙酰化酶(HDACs)表现出抑制作用。
肿瘤抑制基因的上调表达以及与生长刺激信号通路相关的致癌基因的下调表达,提示青蒿素在乳腺癌治疗中的有效性,表明其作为一种有效的药物。